Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
Status:
Completed
Trial end date:
2020-12-19
Target enrollment:
Participant gender:
Summary
High mortality associated with sepsis and Multiple Organ Dysfunction Syndrome (MODS) calls
for alternative, individualized therapies in selected patients that might benefit form
specific interventions. Role of macrolides as potential immunomodulatory treatment in sepsis
is promising, but unclear. Subgroup analysis of previous large-scale clinical trials on
patients with ventilator-associated pneumonia or gram-negative sepsis, showed that addition
of clarithromycin to standard antibiotic therapy conferred a significant survival benefit in
the subgroup of patients with respiratory dysfunction and MODS. The INCLASS study is aiming
to assess the efficacy of intravenous treatment of clarithromycin in the reduction of 28-day
mortality among patients suffering from these entities.